Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system, has scheduled its Q1 2025 financial results release and business update for May 9, 2025.

The company will host a conference call and webcast at 8:30 a.m. EDT to discuss financial results and provide updates on corporate and regulatory developments. The call will be accessible via toll-free numbers for domestic and Israeli callers, with international lines available. A replay will be available for two weeks through the company's investor relations website.

Company to host conference call and webcast at 8:30 a.m. EDT

CARMIEL, Israel, May 5, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx^® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2025 and provide a business and clinical update on May 9, 2025.

Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.

Conference Call Details:

Date:                    Friday, May 9, 2025
Time:                    8:30 a.m. Eastern Daylight Time (EDT)
Toll Free:             1-877-423-9813
International:      1-201-689-8573
Israeli Toll Free:  1-809-406-247
Conference ID:    13753682
Call me™:            https://tinyurl.com/yey23rkc

The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.

Webcast Details:

Company Link:  https://ir.protalix.com/news-events/events
Webcast Link:   https://tinyurl.com/3nn9jh5v
Conference ID: 13753682

Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio^®, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.

Investor Contact

Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com 

Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-first-quarter-2025-financial-and-business-results-on-may-9-2025-302445855.html

SOURCE Protalix BioTherapeutics, Inc.

FAQ

When will Protalix BioTherapeutics (PLX) release its Q1 2025 earnings?

Protalix BioTherapeutics will release its Q1 2025 earnings on May 9, 2025, at 8:30 a.m. EDT.

How can investors access Protalix BioTherapeutics' (PLX) Q1 2025 earnings call?

Investors can access the call through toll-free numbers (1-877-423-9813 for US, 1-809-406-247 for Israel), international line (1-201-689-8573), or via webcast at the company's investor relations website.

What is Protalix BioTherapeutics' (PLX) main technology platform?

Protalix BioTherapeutics uses its proprietary ProCellEx® plant cell-based protein expression system for developing and producing recombinant therapeutic proteins.

How long will the replay of PLX's Q1 2025 earnings call be available?

The replay of the earnings call will be available for two weeks on the Events Calendar of the company's investor relations website.